The active ingredient in LUMRYZ is sodium oxybate. But unlike other oxybate options, you don’t need to wake up in the middle of the night for a second dose. This is because LUMRYZ contains a unique blend of granules that work in 2 ways:

• Immediate-release granules start working as you fall asleep
• Controlled-release granules start working later in place of waking for a second dose

Learn more about LUMRYZ

Yes, LUMRYZ was shown to improve symptoms of cataplexy or excessive daytime sleepiness (EDS) with a once-at-bedtime dose.

See more results from the trial

Everyone responds to treatment differently. In the clinical trial for LUMRYZ,* some participants saw symptom improvements as early as week 3 while others saw symptom improvements at week 13^† after titrating to a higher dose.

*The LUMRYZ double-blind, placebo-controlled clinical trial included participants with narcolepsy treated with LUMRYZ (n=107). The results measured at week 3 (n=88), week 8 (n=77), and week 13 (n=69) showed daytime symptom improvement of participants on the 6-g, 7.5-g, and 9-g doses of LUMRYZ, respectively. Individual results may vary.

^†As seen in participants taking the 9-g dose of LUMRYZ and compared to baseline results at the start of the trial.

Only your healthcare provider can decide if LUMRYZ is right for you. LUMRYZ is approved for the treatment of cataplexy or EDS in adults and children 7 years of age and older with narcolepsy.

For adults, if you’re currently taking an oxybate, your healthcare provider can switch you to LUMRYZ at the closest dose—equal to the amount of medicine you’re taking now, or help you find a dose closest to what your body is used to taking.

For pediatric dosing, please see the full Prescribing Information.

Learn how LUMRYZ is different

No, you can be switched to a starting dose closer to what your body is used to taking. It’s important for your healthcare provider to understand how often you may have had to skip the second dose of your twice-nightly oxybate, as it may be more appropriate to switch to a lower starting dose of LUMRYZ than what you were previously prescribed.

Learn how LUMRYZ is different

With LUMRYZ, you take 1 premeasured packet, once at bedtime. See the Instructions for Use for how to prepare, shake, and take LUMRYZ.

Find more details and watch our step-by-step guide

To help you start the conversation with your healthcare provider, we created a Discussion Guide with key questions to ask and plenty of space to take notes.

Download Doctor Discussion Guide

LUMRYZ is only available after enrollment in the LUMRYZ Risk Evaluation and Mitigation Strategy (REMS) and RYZUP^TM Support Services. Your healthcare provider starts your enrollment, and to complete enrollment you’ll need to sign 2 forms:

• Patient Authorization Form
• LUMRYZ REMS Patient Enrollment Form

You may be asked to sign these forms in the healthcare provider’s office. If not, you may receive two (2) separate emails with instructions for how to complete and e-sign.

Learn more about enrolling in RYZUP

After preparing your LUMRYZ dose, you may notice the mixture does not fully dissolve in water and has a gritty texture with a salty taste. Some granules may stick together and look milky and lumpy even after being thoroughly shaken in the provided mixing cup.

This is because each premeasured dose packet contains a mix of immediate- and controlled-release granules designed to slowly release medicine into the body during sleep so you don’t have to wake for a second dose.

See the Instructions for Use for more on what to expect when taking LUMRYZ.

The most common side effects reported by adult participants in the clinical trial were nausea, dizziness, bedwetting, headache, and vomiting.

In the clinical trial for LUMRYZ, side effects typically occurred when participants started a new dose. Generally, the side effects then declined over time while staying on the same dose.

The safety of LUMRYZ for the treatment of cataplexy or excessive daytime sleepiness in pediatric patients 7 years of age and older with narcolepsy was determined in a well-controlled trial of immediate-release sodium oxybate.

The most common side effects in children include nausea, bedwetting, vomiting, headache, decreased weight, decreased appetite, dizziness, and sleepwalking.

Learn more about side effects

Yes, RYZUP Support Services offers financial support programs for eligible patients, including co-pay assistance for commercially insured patients. Eligible patients may pay as little as $0 co-pay per month.^‡

^‡This offer is valid only for patients who have commercial insurance. Offer not valid for patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs. Additional terms and conditions apply. Download the full terms and conditions of the co-pay program.

See how RYZUP Support Services can help

Financial assistance programs are available. Be sure to talk to your healthcare team about financial assistance programs you may qualify for.

Co-pay Assistance
Your co-pay could be as little as $0 if you have commercial insurance.^§

Temporary Access Program (TAP)
If there is a delay in insurance coverage, you may be eligible for up to 120 days of free LUMRYZ.^II

Patient Assistance Program (PAP)
Treatment is available free of charge to eligible patients who are uninsured or underinsured.^¶

^§This offer is valid only for patients who have commercial insurance. Offer not valid for patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs. Additional terms and conditions apply. Download the full terms and conditions of the co-pay program.

^IIApplies only to eligible, commercially insured patients.

^¶Patient Assistance Program application required. Patient must meet certain financial and other criteria.

No, you can remain on your twice-nightly oxybate until the insurance coverage process for your LUMRYZ prescription is complete.

If there is a delay in insurance coverage, you may be eligible for up to 120 days of free LUMRYZ with the Temporary Assistance Program.^#

^#Applies only to eligible, commercially insured patients.